Intra-articular hyaluronan therapy.

Osteoarthritis affects joint function by altering synovial fluid composition. Hyaluronan is a key component of normal synovial fluid. It supports joint lubrication and load distribution. It also contributes to tissue renewal and inflammation control. In osteoarthritis, hyaluronan levels and molecular weight decrease. This leads to impaired joint function and increased pain. Researchers have proposed replacing hyaluronan in joints. This approach is called viscosupplementation. However, opinions on its effectiveness vary widely.

This review evaluates the role of hyaluronan in joint health and disease. It aims to clarify the therapeutic potential of viscosupplementation. The focus is on recent basic and clinical research. The authors compare findings with earlier studies. They examine mechanisms of action and clinical efficacy. Safety and disease-modifying potential are also addressed. The goal is to provide a balanced synthesis of current evidence. This helps guide clinical decision-making in osteoarthritis treatment.

The authors conducted a literature review of recent and historical studies. They analyzed basic science investigations of hyaluronan function. Clinical trials on viscosupplementation were also included. Data on molecular weight and concentration were compared. Safety profiles from multiple trials were synthesized. Symptomatic outcomes were evaluated across study designs. Disease-modifying effects were assessed using imaging and biomarkers. The review integrates findings to assess overall therapeutic value.

Hyaluronan supports joint homeostasis through multiple mechanisms. Clinical trials show mixed results on pain reduction and function improvement. Some studies report significant short-term symptom relief. Others find no substantial benefit over placebo. Safety data indicate low risk of adverse effects. Molecular weight appears to influence therapeutic response. Long-term disease modification remains unproven. Variability in study design and patient populations complicates interpretation.

Viscosupplementation may provide short-term symptom relief for some patients. Evidence for long-term disease modification is limited. Safety data support its use in appropriate clinical settings. Patient selection and product choice are important factors. Further research is needed to clarify optimal treatment protocols. The authors suggest that viscosupplementation should not replace standard care. It may serve as an adjunct in select cases. The review highlights the need for more consistent study designs.